“Progress with targeted agents in cholangiocarcinoma – reality or myth?”

At the ESMO1 17th World Congress on Gastrointestinal Cancer held in Barcelona in July 2015, Professor Juan Valle, consultant and medical oncologist at The Christie, Manchester UK, and one of AMMF’s medical advisors, spoke about the progress being made in the understanding of cholangiocarcinoma, the studies being carried out to find target agents, and also genomic profiling, in the search for better and mo...

Read More

GWAS Cholangiocarcinoma Study

The Genome-wide Association Study (GWAS) for Cholangiocarcinoma Professor Simon Taylor-Robinson and Dr. Shahid Khan at Imperial College London are collaborating on the GWAS project with the Mayo clinic in the USA1, as one of their ongoing studies in cholangiocarcinoma. If you2 would be interested in donating blood and urine samples for analysis to the Imperial Hepatology & Gastroenterology BioBank...

Read More

The ABC-03 trial

As a result of the landmark ABC-02 study, the Cisplatin and Gemcitabine chemotherapy combination1 is recognised as the standard first-line treatment for those with inoperable biliary tract cancer (cholangiocarcinoma).  However, the search goes on for improvements to this regime. In the ABC-03 study, Cediranib (an anti angiogenic drug1) was added to the Gemcitabine / Cisplatin combination. Unfortu...

Read More

Interim Report from AMMF’s Research Fellow

AMMF has just received an interim report from the Institute of Hepatology in London on the cholangiocarcinoma research work being carried out there by our Research Fellow, Dr Gemma Choy. This work has involved investigating whether the MAPK signalling pathway allows intrahepatic cholangiocarcinoma cell proliferation.  We are very pleased to learn that the project is progressing well with results to ...

Read More

New Cancer Strategy for England published

The report, “Achieving world-class cancer outcomes: a strategy for England 2015-2020”, has just been published and has been widely welcomed by many in the cancer communities, including Cancer52. In January 2015, The Independent Cancer Taskforce1 was set up to develop a five-year strategy for cancer services.  The report is the result of responses to a Call for Evidence,  outputs from 30 workshops, ...

Read More

Cholangiocarcinoma mortality higher than incidence?

The survival rate for cholangiocarcinoma is recognised to be extremely low, but how can mortality be higher than incidence? The statistics in the recently published NCIN1/Cancer522 Rare and Less Common Cancers report show not only that the incidence of cholangiocarcinoma is increasing year on year, but also that the mortality figures for the years 2012 and 2013 are higher than the incidence. This is also r...

Read More

AMMF and the Rare Cancer Report

by Helen Morement A year ago, I was invited to be part of the advisory board for a new collaborative project being undertaken by Public Health England's National Cancer Intelligence Network (NCIN1) and Cancer522. This aim of this project was to produce, for the first time, a list of as many of the rare and less common cancers as possible together with their correct ICD-10 codings3 and their incidence and m...

Read More

AMMF’s latest newsletter …

Our latest newsletter is now in circulation. We share AMMF’s news daily on our website and via social media, especially through our active Facebook page, but producing a newsletter gives us a chance to gather together and review the most outstanding events of the recent past. It also gives us an opportunity to especially remember those we have recently lost cholangiocarcinoma and to thank their ...

Read More

CC Awareness Month 2015 Guest Posts

Thank you to each person who took their courage in both hands and contributed a Guest Post for AMMF’s Facebook page during Cholangiocarcinoma Awareness Month 2015. What incredibly moving stories were shared by those who have lost precious people to cholangiocarcinoma, from those currently undergoing treatment and from all too few “survivors”. It was heartwarming to see the kind and supportive co...

Read More

AMMF Awards Research Fellowship

AMMF awards a Research Fellowship to Dr Pui Man (Gemma) Choy AMMF has agreed to fund a Research Fellowship at the Institute of Hepatology London for a period of two years, beginning March 2015. Grants totalling £82,060 will be made over this two year period to enable Dr Pui Man (Gemma) Choy to continue research on the molecular mechanisms of cholangiocarcinoma development that AMMF has already been suppor...

Read More